CONTEXT: The mechanisms by which testosterone increases hemoglobin and hematocrit are unknown. OBJECTIVE: The aim was to test the hypothesis that testosterone-induced increase in hematocrit is associated with suppression of the iron regulatory peptide hepcidin. PARTICIPANTS: Healthy younger men (ages 19-35 yr; n = 53) and older men (ages 59-75 yr; n = 56) were studied. METHODS: Weekly doses of testosterone enanthate (25, 50, 125, 300, and 600 mg) were administered over 20 wk, whereas endogenous testosterone was suppressed by monthly GnRH agonist administration. Blood and serum parameters from each individual were measured at wk 0, 1, 2, 4, 8, and 20. Longitudinal analyses were performed to examine the relationship between hepcidin, hemoglobin, hematocrit, and testosterone while controlling for potential confounders. RESULTS: High levels of testosterone markedly suppressed serum hepcidin within 1 wk. Hepcidin suppression in response to testosterone administration was dose-dependent in older men and more pronounced than in young men, and this corresponded to a greater rise in hemoglobin in older men. Serum hepcidin levels at 4 and 8 wk were predictive of change in hematocrit from baseline to peak levels. CONCLUSION:Testosterone administration is associated with suppression of serum hepcidin. Greater increases in hematocrit in older men during testosterone therapy are related to greater suppression of hepcidin.
RCT Entities:
CONTEXT: The mechanisms by which testosterone increases hemoglobin and hematocrit are unknown. OBJECTIVE: The aim was to test the hypothesis that testosterone-induced increase in hematocrit is associated with suppression of the iron regulatory peptide hepcidin. PARTICIPANTS: Healthy younger men (ages 19-35 yr; n = 53) and older men (ages 59-75 yr; n = 56) were studied. METHODS: Weekly doses of testosterone enanthate (25, 50, 125, 300, and 600 mg) were administered over 20 wk, whereas endogenous testosterone was suppressed by monthly GnRH agonist administration. Blood and serum parameters from each individual were measured at wk 0, 1, 2, 4, 8, and 20. Longitudinal analyses were performed to examine the relationship between hepcidin, hemoglobin, hematocrit, and testosterone while controlling for potential confounders. RESULTS: High levels of testosterone markedly suppressed serum hepcidin within 1 wk. Hepcidin suppression in response to testosterone administration was dose-dependent in older men and more pronounced than in young men, and this corresponded to a greater rise in hemoglobin in older men. Serum hepcidin levels at 4 and 8 wk were predictive of change in hematocrit from baseline to peak levels. CONCLUSION:Testosterone administration is associated with suppression of serum hepcidin. Greater increases in hematocrit in older men during testosterone therapy are related to greater suppression of hepcidin.
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: S Bhasin; L Woodhouse; R Casaburi; A B Singh; D Bhasin; N Berman; X Chen; K E Yarasheski; L Magliano; C Dzekov; J Dzekov; R Bross; J Phillips; I Sinha-Hikim; R Shen; T W Storer Journal: Am J Physiol Endocrinol Metab Date: 2001-12 Impact factor: 4.310
Authors: Luigi Ferrucci; Richard D Semba; Jack M Guralnik; William B Ershler; Stefania Bandinelli; Kushang V Patel; Kai Sun; Richard C Woodman; Nancy C Andrews; Robert J Cotter; Tomas Ganz; Elizabeta Nemeth; Dan L Longo Journal: Blood Date: 2010-01-15 Impact factor: 22.113
Authors: Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Ahmed A Alkhateeb; Peter D Buckett; Andrew M Gardeck; Jonghan Kim; Shaina L Byrne; Paula G Fraenkel; Marianne Wessling-Resnick Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-04-23 Impact factor: 4.052
Authors: Justine Bacchetta; Joshua J Zaritsky; Jessica L Sea; Rene F Chun; Thomas S Lisse; Kathryn Zavala; Anjali Nayak; Katherine Wesseling-Perry; Mark Westerman; Bruce W Hollis; Isidro B Salusky; Martin Hewison Journal: J Am Soc Nephrol Date: 2013-11-07 Impact factor: 10.121
Authors: Marc Sim; Laura A Garvican-Lewis; Gregory R Cox; Andrew Govus; Alannah K A McKay; Trent Stellingwerff; Peter Peeling Journal: Eur J Appl Physiol Date: 2019-05-04 Impact factor: 3.078
Authors: Iwona Rotter; Danuta I Kosik-Bogacka; Barbara Dołęgowska; Krzysztof Safranow; Magdalena Kuczyńska; Maria Laszczyńska Journal: Environ Geochem Health Date: 2015-08-09 Impact factor: 4.609
Authors: Jordan C Best; Daniel Gonzalez; Thomas A Masterson; Ruben Blachman-Braun; Raghav Pai; Ranjith Ramasamy Journal: Can Urol Assoc J Date: 2021-02 Impact factor: 1.862